Halozyme plunges, Baxter bruised on US FDA call for more HyQ safety data
This article was originally published in Scrip
Executive Summary
Shares of Halozyme plummeted as low as 33.4%, or $3.76, on 16 April after the San Diego-based biotech and its partner Baxter International disclosed that the US FDA wants additional safety data before it will complete its review of the biologics license application (BLA) for HyQ, a combination of immune globulin infusion and recombinant human hyaluronidase (rHuPH20) under investigation to treat primary immunodeficiency disorder.